A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Recruiting Observational Study
Gastroenteropancreatic Neuroendocrine Tumor
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 110
Sex
Any
Study type
Observational
Participants needed
4,023 (estimated)
Sponsor
Novartis Pharmaceuticals · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: 1. Patients with ≥1 International Classification of Diseases Clinical Modification, 10th revision (ICD-10-CM) diagnosis code for GEP-NET between 01 January 2018 and 31 December 2025. The date of the first such claim will be defined as the diagnosis date. 2. Initiation of first-l…
Contacts

Novartis Pharmaceuticals

+41613241111

novartis.email@novartis.com

CONTACT

Novartis Pharmaceuticals

CONTACT